- Home
- CISS vs ATNF Comparison
CISS vs ATNF Comparison
Compare CISS & ATNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- ATNF
- Stock Information
- Founded
- CISS 2022
- ATNF 2016
- Country
- CISS Greece
- ATNF United States
- Employees
- CISS N/A
- ATNF N/A
- Industry
- CISS Marine Transportation
- ATNF Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- ATNF Health Care
- Exchange
- CISS Nasdaq
- ATNF Nasdaq
- Market Cap
- CISS 4.7M
- ATNF 4.1M
- IPO Year
- CISS N/A
- ATNF N/A
- Fundamental
- Price
- CISS $1.02
- ATNF $1.25
- Analyst Decision
- CISS
- ATNF
- Analyst Count
- CISS 0
- ATNF 0
- Target Price
- CISS N/A
- ATNF N/A
- AVG Volume (30 Days)
- CISS 81.4K
- ATNF 84.0K
- Earning Date
- CISS 03-25-2025
- ATNF 03-04-2025
- Dividend Yield
- CISS N/A
- ATNF N/A
- EPS Growth
- CISS N/A
- ATNF N/A
- EPS
- CISS N/A
- ATNF N/A
- Revenue
- CISS $46,661,732.00
- ATNF N/A
- Revenue This Year
- CISS N/A
- ATNF N/A
- Revenue Next Year
- CISS N/A
- ATNF $54.15
- P/E Ratio
- CISS N/A
- ATNF N/A
- Revenue Growth
- CISS 491.48
- ATNF N/A
- 52 Week Low
- CISS $0.90
- ATNF $1.16
- 52 Week High
- CISS $29.75
- ATNF $17.75
- Technical
- Relative Strength Index (RSI)
- CISS 32.70
- ATNF 33.17
- Support Level
- CISS $1.15
- ATNF $1.31
- Resistance Level
- CISS $1.21
- ATNF $1.38
- Average True Range (ATR)
- CISS 0.08
- ATNF 0.06
- MACD
- CISS 0.00
- ATNF 0.01
- Stochastic Oscillator
- CISS 32.43
- ATNF 0.00
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.